

Anti-Drug Antibody (ADA) Bridging ELISA

ADA – Ranibizumab

For use with Anti-Ranibizumab Monoclonal Antibodies catalog #HCA305 and #HCA185

This method provides a procedure for generating an ADA ELISA standard curve with Anti-Ranibizumab Antibody, #HCA305 or Anti-Bevacizumab Antibody, #HCA185 using ranibizumab antibody for capture and detection. Ranibizumab is a monovalent Fab fragment antibody, and was created from the same parent mouse antibody as bevacizumab. Anti-Bevacizumab Antibody #HCA185 also recognizes ranibizumab. The method should always be used in conjunction with product and batch specific information provided with each vial (see product datasheets). This protocol will need to be adjusted for use with different detection methods and immunoassay technology platforms.

Reagents

- BSA
- HISPEC Assay Diluent (#BUF049)
- Human Serum (Sigma-Aldrich, #H4522)
- LYNX Rapid HRP Antibody Conjugation Kit (#LNK001P-LNK006P)
- PBS
 - 136 mM NaCl
 - 2.68 mM KCl
 - 8.1 mM Na₂HPO₄
 - 1.46 mM KH₂PO₄
- PBST
 - PBS with 0.05% Tween 20
- QuantaBlu Fluorogenic Peroxidase Substrate (Thermo Fisher Scientific, #15169)

Materials

- 384-well microtiter plate, black, square flat-bottom wells, for example, Black 384-Well Immuno Plates (Thermo Fisher Scientific, #460518)
- Fluorescence plate reader

96-well plates can be used instead of 384-well plates, (black, flat-bottom wells) for example, Black 96-Well Immuno Plates (Thermo Fisher Scientific, #437111). For the 96-well format, use 100 µl (instead of 20 µl) of antigen, antibodies, or substrate and 300 µl for the blocking step.

Method

1. Prepare detection antibody: conjugate ranibizumab antibody using a LYNX Rapid HRP Antibody Conjugation Kit.
2. Prepare the unconjugated ranibizumab capture antibody at 1 µg/ml in PBS. Coat the required number of wells of a 384-well microtiter plate with 20 µl per well of the prepared ranibizumab, and incubate overnight at 4°C.
3. Wash the microtiter plate five times (5x) with PBST.
4. Block the microtiter plate by adding 100 µl 5% BSA in PBST to each well, and then incubate for 1 hr at RT.
5. Wash the microtiter plate 5x with PBST.
6. For the standard curve, prepare a dilution series of the Anti-Ranibizumab Antibody #HCA305 (AbD16746_hlgG1) or the Anti-Bevacizumab Antibody #HCA185 (AbD17976_hlgG1) in 10% human serum in PBST in triplicate. Final concentration of anti-ranibizumab or anti-bevacizumab antibody should cover the range from 0.5 ng/ml to 10,000 ng/ml. Include a zero anti-ranibizumab or anti-bevacizumab antibody concentration as the background value.
7. Add 20 µl of anti-ranibizumab antibody dilution per well (in triplicate for each standard recommended) and incubate for 1 hr at RT.
8. Wash the microtiter plate 5x with PBST.
9. To each well add 20 µl HRP conjugated ranibizumab diluted to 2 µg/ml in HISPEC Assay Diluent and incubate for 1 hr at RT.
10. Wash the microtiter plate 10x with PBST.
11. Add 20 µl QuantaBlu Fluorogenic Peroxidase Substrate to each well and measure the fluorescence after 30 min.

Bio-Rad is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions. LYNX Rapid Conjugation Kit is a trademark of Bio-Rad Europe, GmbH in certain jurisdictions. All trademarks used herein are the property of their respective owner.



**Bio-Rad
Laboratories, Inc.**

Life Science
Group

Web site bio-rad-antibodies.com

Austria, Germany, Netherlands & Switzerland 49 89 80 90 95 21 **Belgium & Luxembourg** 44 1865 852 357 **Canada & USA** 1 800 424 6723
France 44 1865 852 357 **United Kingdom, Scandinavia & other countries** 44 1865 852 700 **Custom Services** 49 89 80 90 95 45

